Method for treating intraocular malignancies

• US 4,300,557 A
• Filed: 01/07/1980
• Issued: 11/17/1981
• Est. Priority Date: 01/07/1980
• Status: Expired due to Term

• Current Assignee: United States Department Of Health And Human Services
• Original Assignee: United States Department Of Health And Human Services
• Inventors: Refojo, Miguel F., Liu, Hsaio S.
• Primary Examiner(s): ROSENBAUM, C FRED
• Application Number:
  US06/110,045
• Time in Patent Office: 680 Days
• Field of Search: 128/1 R, 128/1.1, 128/1.2, 128/260
• US Class Current: 424/424
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants

Abstract

An improved process for dispensing a lipid soluble labile drug, i.e. 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) by diffusion through a silicone capsule implanted at a periocular site to an intraocular site within an animal body being treated with the drug, the improvements wherein the silicone capsule is provided with a tube sealed at the distal end thereof and provided with longitudinal slit cut through the tube wall inside the capsule for filling the capsule following implantation of the capsule, wherein the capsule is implanted surgically near the site being treated so that the tube is accessible for filling without further surgical procedures and wherein the drug is injected into the capsule through the tube in the form of a solution in a solvent which is non-toxic to the animal being treated, inert with respect to the drug dissolved therein and capable of diffusing from the capsule within 5 hours to leave a residue of the drug in the capsule.

Claims

1. In the process of dispensing a lipid-soluble, labile drug by diffusion through an implantable silicone capsule to a site within an animal body being treated with the drug, the improvements wherein the silicone capsule is provided with a tube sealed at the distal end thereof and provided with a longitudinal slit cut through the tube wall inside the capsule for filling the capsule following implantation of the capsule, wherein the capsule is implanted surgically near the site being treated so that the tube is accessible for filling without further surgical procedures and wherein the drug is injected into the capsule through the tube in the form of a solution in a solvent which is non-toxic to the animal being treated, inert with respect to the drug dissolved therein and capable of diffusing from the capsule within 5 hours to leave a residue of the drug in the capsule.

2. The process of claim 1, wherein the capsule is subsequently refilled with one or more additional portions of the drug dissolved in the solvent.

3. The process of claim 1, wherein the site being treated is the eye, the drug being administered is 1,3-bis(2-chloroethyl)-1-nitrosourea and the solvent absolute ethanol.

4. The process of claim 1, wherein the capsule is in the form of a microballoon having walls 0.1-0.2 mm in thickness.

5. The process of claim 1, wherein the site being treated is the eye, the drug being administered is 1,3-bis(2-chloroethyl)-1-nitrosurea, the solvent is absolute ethanol, the capsule is in the form of a microballoon having walls 0.1-0.2 mm in thickness and the capsule is subsequently refilled with one or more additional portions of BCNU dissolved in absolute ethanol.

6. The process of claim 1 wherein the solvent is absolute ethanol.

7. The process of claim 1 wherein the microballoon has an average length of 8-10 mm, a width of 4-6 mm and walls of 0.1-0.2 mm.